Replies to post #249962 on Biotech Values

[DewDiligence]

[CERE] I love biotech investing :--)
Kiwi

[CABA] I hate investing in biotech :--)
Kiwi

Yes, and yes. That’s why I maintain two tables on this board: one for biotech buyouts, and one for biotech bankruptcies.

[DewDiligence]

Factoid—Ron Renaud has been CEO of three biotech companies acquired by Big Pharma during the past decade: CERE (2023), TBIO (2021), and IDIX (2014). The buyers were ABBV, SNY, and MRK, respectively.

[sab63090]

Kiwi:

I think Dew's reply to you is correct: it's either a moon shot or bankruptcy!

Hope you are doing well!

Steve

PS.....Still waiting on $SWAV...

[DewDiligence]

CERE—(being acquired by ABBV)—reports phase-3 Parkinson’s data:

https://www.globenewswire.com/news-release/2024/04/18/2865216/0/en/Cerevel-Therapeutics-Announces-Positive-Topline-Results-for-Tavapadon-in-Phase-3-Adjunctive-Trial-for-People-Living-with-Parkinson-s-Disease.html

[DewDiligence]

ABBV—(-11%)—reports phase-2 failures_of Emraclidine in schizophrenia

https://finance.yahoo.com/news/abbvie-provides-phase-2-results-133000842.html

AbbVie today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute exacerbation of psychotic symptoms, did not meet their primary endpoint of showing a statistically significant reduction (improvement) in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6.

ABBV acquired Emraclidine in the $8.7B buyout of Cerevel Therapeutics in Dec 2023 (#msg-173374544).